spacer
home > ebr > summer 2003 > biotechnology: breathing new life into drug development
PUBLICATIONS
European Biopharmaceutical Review

Biotechnology: Breathing New Life into Drug Development

As the environment in which they operate becomes more competitive, pharmaceutical companies are finding it increasingly difficult to boost the output of new drugs. In recent years, some of the major companies in the industry have received criticism from those who believe that they lack new ideas and methodologies. They assert that the industry is producing too many new drugs that are similar to each other and offer little clinical advantage over those already on the global market.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Faiz Kermani, Budgets, Proposals and Marketing Executive, and Pietro Bonacossa, Marketing Executive, at Chiltern International, Inc

Dr Faiz Kermani is currently a Budgets, Proposals & Marketing Executive working in business development at Chiltern International. He previously worked in business development at CMR International, examining R&D productivity issues for pharmaceutical industry clients.

He holds a PhD in Immunopharmacology from St Thomas' Hospital, London and a First Class honours degree in Pharmacology with Toxicology from King's College, London.


Pietro Bonacossa is a Marketing Executive at Chiltern International in the USA. He holds a BA degree in International Trade from Auburn University and an MBA in Marketing from Georgia State University.

Prior to joining Chiltern, he spent two years at Turner Broadcasting Systems, working as a Project Co-ordinator for CNN Headline News and as a Public Relations Liaison for CNN.com.

spacer
Dr Faiz Kermani
spacer
spacer
spacer
Pietro Bonacossa
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Optimizing pharmaceutical processes

An increase in requirements from regulatory agencies around the world, combined with a growing demand for drugs in prefilled injections systems a trend that industry experts have projected will continue has led pharmaceutical and biotech supply chains to gain in significance. Well established and optimized processes are crucial for offering uninterrupted market supply. To satisfy its customers a CDMO must foster flexibility, efficiency and safety throughout the entire supply chain. The most important goal for all parties involved in the bio-pharma business is maximization of product quality where even small decisions can make a big difference. Future-oriented pharma processes can add value to any compound.
More info >>

White Papers

Challenges of Analytical Method Transfer in the Pharmaceutical Industry

RSSL

The development and validation of suitable analytical methods is a critical part of the overall drug-development life-cycle. For the majority of products, particularly those that are clinically successful, the transfer of the analytical method between laboratories will be required. This process is designed to verify that a given laboratory is capable of performing a test method for its intended purpose. This can be performed either internally (at the same company), or, with the on-going increasing trend in outsourcing, to an external Contract Research or Development organisation (CRO or CDO).
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement